Abstract
Reverse transcription quantitative polymerase chain reaction (RTqPCR)is currently the most sensitive tool available for the routine monitoring of disease level in patients undergoing treatment for BCRABL1 associated malignancies. Considerable effort has been invested at both the local and international levels to standardise the methodology and reporting criteria used to assess this critical metric. In an effort to accommodate the demands of increasing sample throughput and greater standardization, we adapted the current best-practice guidelines to encompass automation platforms and improved multiplex RT-qPCR technology.
MeSH terms
-
Automation, Laboratory
-
Biomarkers
-
Diffusion of Innovation
-
Fusion Proteins, bcr-abl / blood*
-
Fusion Proteins, bcr-abl / genetics
-
Fusion Proteins, bcr-abl / metabolism
-
High-Throughput Screening Assays* / standards
-
Humans
-
Kinetics
-
Limit of Detection
-
Molecular Probes / metabolism
-
Multiplex Polymerase Chain Reaction
-
Neoplasm Proteins
-
Proto-Oncogene Proteins c-abl / blood
-
Proto-Oncogene Proteins c-abl / genetics
-
Proto-Oncogene Proteins c-abl / metabolism
-
Reverse Transcriptase Polymerase Chain Reaction
Substances
-
Biomarkers
-
Molecular Probes
-
Neoplasm Proteins
-
abl-bcr fusion protein, human
-
Fusion Proteins, bcr-abl
-
Proto-Oncogene Proteins c-abl